In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Serono's Dealmaking Roll continues

Executive Summary

Serono's licensing of the exclusive rights to market Genentech Inc.'s Phase III psoriasis drug, Raptiva, outside of the US, Japan, and certain Asian countries, went far to quell rumblings within the investment community that the Swiss-based biotech needed to beef up its late-stage pipeline. The agreement also comes amidst a flurry of dealmaking which sends a clear message that the company's management is willing to act aggressively to fill in gaps in all aspects of the business from discovery to product development to commercialization.

You may also be interested in...



The Serono/Pfizer Rebif Co-Promotion: Just Act One?

Analysts generally expressed the view that Pfizer and Serono will both benefit from their agreement to co-promote the multiple sclerosis drug, Rebif. But some question whether the sales and marketing boost Pfizer will give the specialty drug justifies its $200 million upfront payment, or, for that matter, the estimated 35%-40% commission on sales that Serono will be required to pay Pfizer.

Medtech Multinationals Up Pace Of Localization Strategies In China

China-specific go-to-market strategies are helping global medtechs access the fast-growing medical device market in China, where localization has become the buzzword for foreign players, writes news and analysis portal Omdia.

Lack Of Interchangeability No Barrier For Amjevita, Says Amgen Executive

While Amgen’s Amjevita (adalimumab-atto) has yet to secure an interchangeability designation, company executives appear confident this will have little impact on their Humira biosimilar’s competitiveness overall.

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

IV001965

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel